Publications & Research

Peer review publications in journals

 

1. Daskalakis K, Tsoli M, Srirajaskanthan R, Chatzellis E, Alexandraki KI, Angelousi A,

    Pizanias M, Randeva H, Kaltsas G, Weickert M. Lung Metastases in Patients with

    Well-Differentiated Gastroenteropancreatic Neuroendocrine Neoplasms: An

    Appraisal of the Validity of Thoracic Imaging Surveillance. Neuroendocrinology. 2019 Jan

    23. doi: 10.1159/000497183.

 

2. Alexandraki KI, Pizanias M, Uri I, Thomas D, Page T, Kolomodi D, Low CS,

    Adesanya O, Tsoli M, Gross DJ, Randeva H, Srirajaskanthan R, Grozinsky-

    Glasberg S, Kaltsas G, Weickert MO. The prognosis and management of

    neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical

    practice. Endocrine. 2019 Jan 11. doi: 10.1007/s12020-019-01838-8. [Epub ahead of print]

 

3. Basuroy R, Bouvier C, Ramage JK, Sissons M, SrirajaskanthanR. Delays and routes

    to diagnosis of neuroendocrine tumours.. BMC Cancer. 2018 Nov 16;18(1):1122. 

 

4. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary

    cholangitis: development and validation of the UDCA Response Score. Carbone M,

    Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, Spicer A, Badrock J,

    Bernuzzi F, Cardinale V, Ainsworth HF, Heneghan MA, Thorburn D, Bathgate A,

    Jones R, Neuberger JM, Battezzati PM, Zuin M, Taylor-Robinson S, Donato MF,

    Kirby J, Mitchell-Thain R, Floreani A, Sampaziotis F, Muratori L, Alvaro D, Marzioni

    M, Miele L, Marra F, Giannini E, Gaudio E, Ronca V, Bonato G, Cristoferi L,

    Malinverno F, Gerussi A, Stocken DD, Cordell HJ, Hirschfield GM, Alexander GJ,

    Sandford RN, Jones DE, Invernizzi P, Mells GF; Italian PBC Study Group and the

    UK–PBC Consortium. Lancet Gastroenterol Hepatol. 2018

 

5. Presenting symptoms and delay in diagnosis of gastrointestinal and pancreatic

    Neuroendocrine tumours, Basuroy et al, 2017 Neuroendocrinology

 

6. Pavel et al, Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy in the

    TELECAST Phase 3 Trial, 2017, Endocrine related Cancer

 

7. Mills et al, Tumour Diameter is Not Reliable for Management of Non-Secreting

    Pancreatic Neuroendocrine Tumours, 2017 Endocrine Connections

 

8. Basuroy et al. Ileo-colonic neuroendocrine tumours identified in the English bowel

    cancer screening programme  (BCSP) (CDI-00376-2017), , 2017 Colorectal Disease

 

9. Strosberg J 1 , El-Haddad G 1 , Wolin E 1 , Hendifar A 1 , Yao J 1 , Chasen B 1 , Mittra E 1 , Kunz PL 1 , Kulke

    MH 1 , Jacene H 1 , Bushnell D 1 , O'Dorisio TM 1 , Baum RP 1 , Kulkarni HR 1 , Caplin M 1 , Lebtahi R 1 ,

    Hobday T 1 , Delpassand E 1 , Van Cutsem E 1 , Benson A 1 , Srirajaskanthan R 1 , Pavel M 1 , Mora J 1 ,

    Berlin J 1 , Grande E 1 , Reed N 1 , Seregni E 1 , Öberg K 1 , Lopera Sierra M 1 , Santoro P 1 , Thevenet T 1 ,

    Erion JL 1 , Ruszniewski P 1 , Kwekkeboom D 1 , Krenning E 1 ; NETTER-1 Trial Investigators. Phase 3

    Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 12;376(2):125-135.

 

10. Basuroy R, Srirajaskanthan R, Ramage JK Neuroendocrine Tumors. Gastroenterol Clin North

     Am. 2016 Sep;45(3):487-507. doi: 10.1016/j.gtc.2016.04.007

 

11. McLauchlan J, Innes H, Dillon JF, Foster G, Holtham E, McDonald S, Wilkes B,

     Hutchinson SJ, Irving WL; HCV Research UK Steering Committee Cohort Profile:

     The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank.

     Int J Epidemiol. 2017 Oct 1;46(5):1391-139

 

12. Basuroy R, Haji A, Ramage JK, Quaglia A, Srirajaskanthan R. Review article: the investigation

     and management of rectal neuroendocrine tumours. Aliment Pharmacol Ther. 2016

     Aug;44(4):332-45. doi: 10.1111/apt.13697. Review.

 

13. Silaschi M, Barr J, Chaubey S, Nicou N, Srirajaskanthan R, Byrne J, Ramage J, MacCarthy P,

     Wendler O. Optimized Outcomes Using a Standardized Approach for Treatment of Patients

     with Carcinoid Heart Disease. Neuroendocrinology. 2016 Apr 21. [Epub ahead of print]

 

14. Cordell HJ, Han Y, Mells GF, Li Y, Hirschfield GM, Greene CS, Xie G, Juran BD, Zhu D, Qian DC,

     Floyd JA, Morley KI, Prati D, Lleo A, Cusi D; Canadian-US PBC Consortium.; Italian PBC

     Genetics Study Group.; UK-PBC Consortium., Gershwin ME, Anderson CA, Lazaridis KN,

     Invernizzi P, Seldin MF, Sandford RN, Amos CI, Siminovitch KA. International genome-wide

     meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic

     pathways. Nat Commun. 2015 Sep 22;6:8019. doi: 10.1038/ncomms9019.

 

15. Ron Basuroy, Debashis Sarker, Alberto Quaglia, Rajaventhan Srirajaskanthan,

     and John Ramage Personalized medicine for gastroenteropancreatic

     neuroendocrine tumors: a distant dream? International Journal of Endocrine

     Oncology, 2015 ,Vol. 2, No. 3 , Pages 201-215

 

16. Basuroy R, Srirajaskanthan R, Prachalias A, Quaglia A, Ramage JK. Letter: the

     response to somatostatin analogues in neuroendocrine tumours is influenced by Ki67

     score--authors' reply. Aliment Pharmacol Ther. 2015 Oct;42(8):1034-5.

 

17. Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, Griffiths L, Lim R,

     Trembling P, Williamson K, Wareham NJ, Aldersley M, Bathgate A, Burroughs AK,

     Heneghan MA, Neuberger JM, Thorburn D, Hirschfield GM, Cordell HJ, Alexander

     GJ, Jones DE, Sandford RN, Mells GF; and the members of the UK-PBC

     Consortium. The UK-PBC risk scores: Derivation and validation of a scoring system

     for long-term prediction of end-stage liver disease in primary biliary cirrhosis.

     Hepatology. 2015

 

18. Kaupp- Roberts S, Srirajaskanthan R, Ramage JK. Symptoms and Quality of Life in

     Gastroenteropancreatic NET. EMJ Oncol. 2015;34-40

 

19. Wu J, Srirajaskanthan R, Ramage J. Rectal Neuroendocrine Tumours. Digestive

     endosc, 2014:532-3

 

20. Basuroy R, Srirajaskanthan R, Prachalias A, Quaglia A, Ramage JK. Review article:

     the investigation and management of gastric neuroendocrine tumours. Aliment

     Pharmacol Ther. 2014:1071-84

 

21. R. Srirajaskanthan, A. Ahmed, A. Prachalias, P. Srinivasan, N. Heaton, N. Jervis, A.

     Quaglia, G. Vivian, J.K Ramage. ENETS TNM staging predicts prognosis in small

     bowel neuroendocrine tumours. ISRN Oncology, 2013.

 

22. R. Basuroy, R. Srirajaskanthan, J.K Ramage. A multimodal approach to the

     management of neuroendocrine tumour liver metastases. International journal of

     hepatology, 2012: 819193

 

 

23. S. Sofroniadou, T. Kassimatis, R. Srirajaskanthan, J. Reidy, D. Goldsmith. Long-term

     safety and efficacy of renin-angiotensin blockade in atherosclerotic renal artery

     stenosis. Int. Uro Nephrol, 2012, 44:1451-9.

 

24. R. Srirajaskanthan, D. Vallini. Azathioprine induced hepatitis in patients with

inflammatory bowel disease. International Journal of Clinical Pharmacy, 2011

 

25. R.Srirajaskanthan, S.Easdale. Novel imaging techniques in management and

     diagnosis of neuroendocrine tumours. J Surg Oncol. 2011, 33(5):724-5

 

26. R. Srirajaskanthan, K. Agarwal, J. Karanyi. Massive gastrointestinal bleed in patient

     with primary sclerosing cholangitis. Gastroenterology, 2011 140(5):e7-8

 

27. R. Srirajaskanthan, D. Shanmugabavan, J.K Ramage. Easily missed. Carcinoid

     syndrome. BMJ, 2010; 341:603-4.

 

28. S. Soni, R. Srirajaskanthan, S. Alexander, S.B Lucas, T. Wong, and J.A White

     Lymphogranuloma venereum proctitis masquerading as inflammatory bowel disease

     in 12 homosexual men. Alimentary, Pharmacology and Therapeutics, 2010; 32:59-65.

 

29. R. Srirajaskanthan, I. Kayani, J. Soh, A.M Quigley, M.E Caplin, J. Bomanji . The role

     of 68 Ga-DOTATATE PET in patients with neuroendocrine tumours and negative or

     equivocal 111 In-DTPA-octreotide scintigraphy. Journal of Nuclear medicine, 2010;

     51:875-82.

 

30. R. Srirajaskanthan, M.E Caplin, M.G Waugh, J. Watkins, J.J Hsuan, N. Beaumont.

     Identification of Mac-2BP as a putative marker of neuroendocrine tumours from the

     analysis of cell line secretomes. Molecular and Cellular Proteomics, 2010; 9:656-66.

 

31. R. Srirajaskanthan, R. Conn, C. Bulwer, P. Irving. The Blatchford scoring system

     enables accurate risk stratification of patients with upper gastrointestinal

     haemorrhage. International Journal of Clinical Practice, 2010; 64:868-74

 

32. R. Srirajaskanthan, T. Shah, J. Watkins, L. Marelli, A. Quaglia, K. Khan, R. Sim, D.

     Hochhauser, M.E Caplin. The expression ErbB family of receptors in Neuroendocrine

     Tumours. Oncology reports. 2010; 23: 909-15.

 

33. P.A Berry, R. Srirajaskanthan, S.H Anderson. An urgent call to the MR scanner -

     potential dangers of capsular endoscopy. Clin Gastroenterol Hepatol. 2009, 2010;

     8(5):26.

 

34. C. Toumpanakis, D.J Hochhauser, L. Marelli, R. Srirajaskanthan, J. Soh, P. Davies,

     J. Buscombe, M.E Caplin. Long term results of patients with malignant carcinoid

     syndrome receiving Octreotide LAR. Alimentary Pharmacology & Therapeutics,

     2009. 30(7):733-40.

 

35. R. Srirajaskanthan, G. Dancy, A. Hackshaw, M.E Caplin, T. Meyer. Circulating

     Angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates

     with disease burden and prognosis. Endocrine related cancer, 2009. 16(3):967-76

 

36. R. Srirajaskanthan, C. Toumpanakis, T. Meyer, M.E Caplin Review article: Future

     therapies for management of metastatic gastroenteropancreatic neuroendocrine

     tumours. Alimentary Pharmacology & Therapeutics. 2009 1; 29:1143-54.

 

37. R. Srirajaskanthan, L. Marelli, A. Karpathakis, C. Toumpanakis, T. Meyer, J.

     Buscombe, M.Dusmet, M.E.Caplin. Bronchial carcinoid tumours: Clinical features

     and management in a series of 45 patients. Lung cancer. 2009; 65:68-73.

 

38. R. Srirajaskanthan, J. Watkins, L. Marelli, M.E Caplin. Co-expression of somatostatin

     and dopamine receptors in neuroendocrine tumours, an immunohistochemical study.

     Neuroendocrinology 2009; 89:308-14.

 

39. R. Srirajaskanthan, M. McStay, C. Toumpanakis, T. Meyer, M.E Caplin. Parathyroid

     hormone related peptide (PTHrP) secreting pancreatic neuroendocrine tumours:

     case series and literature review. Neuroendocrinology. 2009; 89:48-55.

 

40. T Shah, R Srirajaskanthan, M Bhogal, C Toumpanakis, T Meyer, A Noonan, C

     Witney-Smith, T Amin, P Bhogal, N Sivathasan, B Warner, D H, M.E Caplin. Alpha

     fetoprotein and human chorionic gonadotrophin-β are prognostic tumour markers in

     patients with neuroendocrine tumours. British Journal of Cancer; 99:72-7.

 

41. R. Srirajaskanthan, C. Toumpanakis, M. Dusmet, M.E Caplin. A review of thymic

     tumours. Lung cancer. 2008; 60:4-13.

 

42. T. Shah, I. Kulakiene, V.S Warbey, A.M Quigley, R. Srirajaskanthan, C.

     Toumpanakis, D. Hochhauser, J. Buscombe, M.E Caplin. The role of

     99mTechnetium-depreotide in the management of neuroendocrine tumours. Nucl

     Med Commun. 2008; 29:436-40.

 

43. M.C.Y. Wong, B. Portmann, R. Sherwood, O. Niemela, H. Koivisto, S. Parkkila, K.

     Trick, M.R L’Abbe ,J. Wilson, P.R Dash, R. Srirajaskanthan, V.R Preedy, H.

     Wiseman. The cytoprotective effect of alpha-tocopherol and daidzein against D-

     galactosamine-induced oxidative damage in the rat liver. Metabolism; 2007 56:865-75.

 

44. R. Srirajaskanthan, V.R Preedy. Alcohol as a toxic and disease forming agent: Not

     just the liver and brain and not every drinker. Journal of Nutritional and

     Environmental Medicine. 2007; 17 (2): 1-13.

 

45. R. Srirajaskanthan, P. Hanek, D. Tripathi, P. Mairs. An obscure cause of

     gastrointestinal bleeding. Gastroenterology Today, 2007 17(1): 19-21.

 

46. R. Srirajaskanthan, V.R Preedy. Diagnosis and management of Alcoholic liver

     disease. Clinical effectiveness in Nursing 2006; 9:280-285

 

47. Biochemical markers of alcoholism and their clinical effectiveness. R.

     Srirajaskanthan, V.R Preedy. Clinical effectiveness in nursing 2006; 9 sup 3: 280-285

 

48. R. Srirajaskanthan, T. Winter, AF. Muller Thrombosis in inflammatory bowel disease.

     European Journal of Gastroenterology and Hepatology. 2005; 17:697-700.

 

49. B. Afalzi, R.S Bakri, R. Srirajaskanthan, A. Covic, P. Bharma-Ariza, W. Park, M.

     Sriharan, N. Dalton, A. Wierzbicki, M. Crook, D.G Goldsmith. Elevated plasma sialic

     acid in renal transplant patients with cardiovascular disease. Clinical Transplantation

     2004; 18:201-204.

 

50. R. Srirajaskanthan, D.G Goldsmith. Atherosclerotic renal artery stenosis-the challenge of patient mortality.        

     Journal of renovascular disease 2003: 2; 3-9.